News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Investors
Overview
Rights Issue / Företrädesemission 2025
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Rights Issue 2025
Career
Contact
News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Investors
Overview
Rights Issue / Företrädesemission 2025
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Rights Issue 2025
Career
Contact
Home
/
Investors
/
The Share
/
Rights issues
Overview
Rights Issue / Företrädesemission 2025
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Previous Share Issuances
Warrants of series TO 3
Rights issue 2022
Rights issue 2020
Redemption of Subscription Warrants and payment for shares, May 2019
Rights issue 2018
Rights issue in connection with listing on ”Aktietorget”, October 2015
Redemption of Subscription Warrants and payment for shares, December 2016
